Search results for "AGENTS"

showing 10 items of 7330 documents

Lifestyle changes in cancer patients undergoing curative or palliative chemotherapy: is it feasible?

2017

This study aimed to explore the feasibility of an individualized comprehensive lifestyle intervention in cancer patients undergoing curative or palliative chemotherapy.At one cancer center, serving a population of 180,000, 100 consecutive of 161 eligible newly diagnosed cancer patients starting curative or palliative chemotherapy entered a 12-month comprehensive, individualized lifestyle intervention. Participants received a grouped startup course and monthly counseling, based on self-reported and electronically evaluated lifestyle behaviors. Patients with completed baseline and end of study measurements are included in the final analyses. Patients who did not complete end of study measurem…

AdultCounselingMalemedicine.medical_specialtyMEDLINEAntineoplastic Agents03 medical and health sciences0302 clinical medicineFeeding behaviorNeoplasmsLifestyle interventionmedicineHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineExerciseAgedbusiness.industryCancerHematologyGeneral MedicinePalliative chemotherapyFeeding BehaviorMiddle Agedmedicine.diseaseClinical trialOncology030220 oncology & carcinogenesisFeasibility StudiesFemalebusinessRisk Reduction BehaviorActa oncologica (Stockholm, Sweden)
researchProduct

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

2003

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…

AdultCyclopropanesMalePulmonary and Respiratory MedicineBudesonideAdolescentmedicine.drug_classAcetatesSulfidesFluticasone propionatechemistry.chemical_compoundDouble-Blind Methodimmune system diseasesAdministration InhalationHumansMedicineSingle-Blind MethodAnti-Asthmatic AgentsBudesonideMontelukastAgedAsthmaLeukotriene E4business.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeEditorialchemistryAnesthesiaQuinolinesCorticosteroidDrug Therapy CombinationFemaleOnset of actionSalmeterolbusinessmedicine.drugThorax
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Genomic analysis of the emergence and evolution of multidrug resistance during a Klebsiella pneumoniae outbreak including carbapenem and colistin res…

2014

et al.

AdultDNA BacterialMaleMicrobiology (medical)CarbapenemAntibiotic resistanceKlebsiella pneumoniaeMolecular Sequence DataNonsense mutationFosfomycinDisease OutbreaksMicrobiologyEvolution MolecularPlasmidAntibiotic resistanceMutation RateOutbreak genomicsmedicineHumansPharmacology (medical)AgedPharmacologyGeneticsbiologyColistinHypermutationSequence Analysis DNAMiddle Agedbiochemical phenomena metabolism and nutritionbiology.organism_classificationDrug Resistance MultipleAnti-Bacterial AgentsKlebsiella InfectionsMultiple drug resistanceKlebsiella pneumoniaeInfectious DiseasesCarbapenemsKlebsiella pneumoniae genomeColistinbacteriaFemaleGenome Bacterialmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

OXA-163-Producing Klebsiella pneumoniae in Cairo, Egypt, in 2009 and 2010

2012

ABSTRACT Two genetically unrelated OXA-163-carrying Klebsiella pneumoniae strains were identified from two infection cases in June 2009 and May 2010 in Cairo, Egypt. OXA-163-producing Enterobacteriaceae had been previously reported in Argentina only. Both patients had no history of travel abroad. The emergence of this newly recognized OXA-48-related β-lactamase able to hydrolyze cephalosporins and carbapenems is especially worrying in a geographic area where OXA-48 is endemic and effective surveillance for antibiotic resistance is largely unaffordable.

AdultDNA BacterialMaleMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaOXA-163EpidemiologyKlebsiella pneumoniaemedicine.drug_classMolecular Sequence DataCephalosporinSettore MED/42 - Igiene Generale E Applicatabeta-Lactam Resistancebeta-LactamasesTravel abroadMicrobiologyAntibiotic resistancepolycyclic compoundsmedicineHumansOXA-163; Klebsiella pneumoniaebiologyGeographic areaHydrolysisSequence Analysis DNAKlebsiella infectionsbiochemical phenomena metabolism and nutritionbiology.organism_classificationVirologyAnti-Bacterial AgentsCephalosporinsKlebsiella InfectionsKlebsiella pneumoniaeCarbapenemsbacteriaEgyptFemaleJournal of Clinical Microbiology
researchProduct

Clinical and Microbiologic Effects of Subgingival Controlled-Release Delivery of Chlorhexidine Chip in the Treatment of Periodontitis: A Multicenter …

2008

Background: The main therapeutic approach for periodontal diseases is mechanical treatment of root surfaces via scaling and root planing (SRP). Multicenter clinical trials have demonstrated that the adjunctive use of a chlorhexidine (CHX) chip is effective in improving clinical results compared to SRP alone. However, some recent studies failed to confirm these clinical results, and conflicting results were reported regarding the effects of the CHX chip on subgingival microflora. The aim of this study was to provide further data on the clinical and microbiologic effects of CHX chips when used as an adjunct to SRP. Methods: A total of 116 systemically healthy individuals with moderate to adva…

AdultDNA BacterialMalemedicine.drug_classBleeding on probingColony Count MicrobialDental PlaqueDentistryStatistics Nonparametriclaw.inventionBacteria AnaerobicScaling and root planingAntisepticRandomized controlled triallawChlorhexidine/therapeutic use controlled clinical trial drug delivery system periodontitis/therapymedicineHumansSingle-Blind MethodperiodontitisAgedPeriodontitischlorexidine; periodontitis; periodontitis/therapy; controlled clinical trial; drug delivery systems; chlorhexidine/therapeutic usebusiness.industryChlorhexidineChlorhexidinePeriodontologyMiddle Agedmedicine.diseaseClinical trialDelayed-Action PreparationsMultivariate AnalysisAnti-Infective Agents LocalDental ScalingPeriodonticsFemalePeriodontal Indexmedicine.symptombusinessmedicine.drugJournal of Periodontology
researchProduct

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients.

1995

In a significant number of patients affected by the irritable bowel syndrome, an adverse reaction to food is proposed to be a causative factor. A diet that eliminates the offending foods is the obvious treatment for such adverse reactions. Compliance with a dietetic regimen is often poor and sometimes not completely free from risks.Since the diarrheic type of irritable bowel syndrome seems mainly affected by food intolerance, and previous observations suggested that oral cromolyn sodium is effective in such patients, a multicenter therapeutic trial in the diarrheic type of irritable bowel syndrome was carried out in 346 of 409 patients with this disease, to evaluate the effects of oral crom…

AdultDiarrheaMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAdministration OralColonic Diseases FunctionalGastroenterologyOral administrationInternal medicineElimination dietAnti-Allergic AgentsCromolyn SodiummedicineHumansAdverse effectIrritable bowel syndromeAgedAged 80 and overChemotherapybusiness.industrydigestive oral and skin physiologyGastroenterologyCromolyn SodiumMiddle Agedmedicine.diseasePrognosisDiarrheaTreatment OutcomeMulticenter studyFemalemedicine.symptombusinessFood HypersensitivityScandinavian journal of gastroenterology
researchProduct

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease

2007

Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a max…

AdultDiarrheaMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsAdolescentCmaxGraft vs Host DiseaseOpportunistic InfectionsGastroenterologySex FactorsDouble-Blind MethodPharmacokineticsOral administrationInternal medicinemedicineHumansTransplantation HomologousPharmacology (medical)MycosisAgedbusiness.industryBody WeightRacial GroupsAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesAcute DiseaseChronic DiseaseFemalebusinessFluconazolemedicine.drugPharmacotherapy
researchProduct

Functional outcome in bipolar disorder: the role of clinical and cognitive factors.

2007

Introduction:  Few studies have examined the clinical, neuropsychological and pharmacological factors involved in the functional outcome of bipolar disorder despite the gap between clinical and functional recovery. Methods:  A sample of 77 euthymic bipolar patients were included in the study. Using an a priori definition of low versus good functional outcome, based on the psychosocial items of the Global Assessment of Functioning (GAF, DSM-IV), and taking also into account their occupational adaptation, the patients were divided into two groups: good or low occupational functioning. Patients with high (n = 46) and low (n = 31) functioning were compared on several clinical, neuropsychologica…

AdultEmploymentMalemedicine.medical_specialtyBipolar DisorderGlobal Assessment of FunctioningNeuropsychological TestsSeverity of Illness IndexAdaptation PsychologicalmedicineHumansPsychologyBipolar disorderEffects of sleep deprivation on cognitive performancePsychiatryBiological PsychiatryDemographyNeuropsychologyCognitionmedicine.diseaseExecutive functionsAntidepressive AgentsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthFemaleVerbal memoryPsychologyCognition DisordersPsychosocialSocial AdjustmentClinical psychologyAntipsychotic AgentsBipolar disorders
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct